Sigilon Therapeutics to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform, today announced that Chief Executive Officer, Rogerio Vivaldi, M.D., will participate in three upcoming virtual investor conferences.

Presentation Details:

Event: BTIG Virtual Biotechnology Conference
Date: Monday, August 10, 2020
Time: 9:00 AM ET
Details: Fireside chat

Event: Canaccord Genuity 40th Annual Growth Conference
Date: Thursday, August 13, 2020
Time: 1:30 PM ET
Details: Corporate presentation

Event: Oppenheimer Private Life Sciences Company Call Series
Date: Wednesday, August 19, 2020
Time: 9:30 AM ET
Details: Corporate presentation

About Sigilon Therapeutics

Sigilon Therapeutics seeks to develop functional cures for chronic diseases through its Shielded Living Therapeutics™ platform. Sigilon’s product candidates consist of novel human cells engineered to produce the crucial proteins, enzymes or factors needed by patients living with chronic diseases such as hemophilia, diabetes and lysosomal disorders. The engineered cells are protected by Sigilon’s Afibromer™ biomaterials matrix, which shields them from immune rejection and fibrosis. Sigilon was founded by Flagship Pioneering in conjunction with Daniel Anderson, Ph.D., and Robert Langer, Sc.D., of the Massachusetts Institute of Technology.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200807005081/en/

Investor Contact
Glenn Reicin
Sigilon Therapeutics, Chief Financial Officer
[email protected]
646-696-4344

Media Contact
Amy Bonanno
Solebury Trout
[email protected]
914-450-0349

Source: Sigilon Therapeutics, Inc.

You May Also Be Interested In

• TASKING and WITTENSTEIN high integrity systems Enable OS-Aware Timing Analysis Without Hardware-Based Trace
• Restart Life Sciences Announces Holy Crap's Amazon U.S. Rollout Alongside Next-Generation Protein and Sampling Innovations
• Molecular Targeting Technologies Receives Pharma Tech Outlook’s 2026 “Radiopharmaceutical Therapy Solution of the Year” Award for EvaThera™